The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 11)
Target Advancement Program, 2018
Two proteins, PINK1 and parkin, prevent cell death by breaking down damaged mitochondria, cell's energy generators. Mutations in the PINK1/PRKN genes - genetic changes that render these proteins unable to break down damaged mitochondria -- cause inherited Parkinson's disease (PD). We recently found that in the striatum -- a brain region involved in PD -- mitochondria in nerve endi...
Researchers: Kelly Lynn Stauch, PhD
Therapeutic Pipeline Program, 2017
Pre-clinical Development of LBT-3627, a Potential Neuroprotective and Anti-inflammatory Therapy for Parkinson's Disease
Adaptive and innate immune responses play important roles in neuroinflammation and can be harnessed to improve outcomes in Parkinson's disease (PD). Daily administration of LBT-3627 increases function of the vasoactive intestinal peptide receptor 2 (VPAC2), which affects the immune system by turning neurotoxic (causes nervous system damage) activities to neurotrophic (promotes ner...
Research Grant, 2017
Promising Outcomes of Original Grant:
In our original proposal, we identified two chemical scaffolds (protein support structures) as dopamine receptor 4 (D4R) antagonists (compounds that block the activity of dopamine) and optimized their strength and ability to pass into the brain. We then tested the lead molecule in a pre-clinical model of L-DOPA-induced dyskinesias (LIDs), disabling involuntary ...
Researchers: Corey R. Hopkins, PhD
Research Grant, 2016
Mutations in the gene encoding the protein parkin cause an inherited form of Parkinson's disease (PD). Parkin plays a neuroprotective role in response to stresses that affect the ability of neurons to produce energy (ATP) in mitochondria (powerhouses of the cell). Parkin also regulates protein recycling in the cell. To exert its effects, parkin must be activated. By studying pre-c...
Researchers: Howard Steven Fox, MD, PhD
Research Grant, 2015
The adaptive and innate immune responses play intricate roles in modulating neuroinflammation and may be harnessed for neuroprotection from Parkinson's disease. We have developed a novel modulator (VPAC2 agonist) that transforms adaptive immune activities from neurotoxic to neurotrophic (supporting growth). This project aims to determine pharmacokinetic and pharm...